What to watch with AMH and longevity?

AMH (anti-Müllerian hormone) is primarily a marker of ovarian reserve and does not directly predict longevity. Low AMH indicates diminished follicle count, which is linked to earlier menopause. Observational studies suggest later menopause is associated with slightly longer lifespan, but also with increased risks of breast and endometrial cancer. The evidence for a direct AMH–longevity axis is weak and based on indirect associations. AMH reference ranges vary by age, assay, and population, so a single measurement is not clinically useful for longevity prediction. Instead, focus on validated biomarkers (HbA1c, CRP, lipids, telomere length) and lifestyle factors (diet, exercise, sleep). Be cautious of commercial tests marketing AMH as a 'longevity biomarker' – this is not evidence-based.